Suppr超能文献

青光眼引流管植入的“串联双巩膜隧道”技术

"Double scleral tunnel in tandem" technique for glaucoma drainage tube implants.

作者信息

Brouzas Dimitrios, Dettoraki Maria, Andreanos Konstantinos, Nomikarios Nikolaos, Koutsandrea Chryssanthi, Moschos Marilita M

机构信息

First Department of Ophthalmology, National and Kapodistrian University of Athens, 154 Mesogion Avenue, 11527, Athens, Greece.

出版信息

Int Ophthalmol. 2018 Dec;38(6):2349-2356. doi: 10.1007/s10792-017-0733-x. Epub 2017 Oct 23.

Abstract

PURPOSE

To describe a new technique of Ahmed glaucoma valve implantation in patients with refractory glaucoma and present the long-term results.

METHODS

Twenty-eight eyes of 28 patients with refractory glaucoma participated in the study. "Double scleral tunnel in tandem" technique was used for glaucoma valve implantation in all patients. The technique consists of the formation of two scleral tunnels in tandem so as to completely cover the extraocular part of valve's tube and facilitate a parallel to the iris placement of the intraocular part of the tube.

RESULTS

Postoperative hypotony developed in two (7.1%) cases which resolved within 3 days in all cases. One (3.6%) eye manifested postoperative hyphema that resolved without complications within a week, and two (7.1%) cases presented with exposure of the tube. The average highest postoperative intraocular pressure (IOP) during the follow-up period was 19 mmHg (range 8-38 mmHg) without medications, and the average IOP at the last follow-up visit was 14.5 mmHg (range 8-22 mmHg). Additional treatment for IOP control was necessary in 11 (39.3%) cases. The average follow-up period was 60 months.

CONCLUSION

This novel technique was found to be easy to master, effective and with low cost and rate of complications.

摘要

目的

描述一种用于难治性青光眼患者的新型 Ahmed 青光眼引流阀植入技术,并展示其长期效果。

方法

28例难治性青光眼患者的28只眼参与了本研究。所有患者均采用“串联双巩膜隧道”技术进行青光眼引流阀植入。该技术包括串联形成两个巩膜隧道,以完全覆盖引流阀导管的眼外部分,并便于导管眼内部分平行于虹膜放置。

结果

2例(7.1%)出现术后低眼压,所有病例均在3天内缓解。1只眼(3.6%)出现术后前房积血,1周内无并发症自行消退,2例(7.1%)出现导管外露。随访期间术后最高平均眼压为19 mmHg(范围8 - 38 mmHg),未使用药物,最后一次随访时平均眼压为14.5 mmHg(范围8 - 22 mmHg)。11例(39.3%)患者需要额外的眼压控制治疗。平均随访期为60个月。

结论

该新技术易于掌握、有效,且成本低、并发症发生率低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验